1. Generics Bulletin
  2. >>Business

Mylan Reveals First Steps For Viatris As Key Date Approaches

Q3 Results Published, Mylan’s Final Earnings Update

 
• By Dean Rudge

Presenting its last ever financial earnings as a standalone company, Mylan revealed plans to host an Investor Day in the first quarter of next year to discuss the strategic direction of Viatris, Mylan’s proposed combination with Pfizer’s Upjohn which is due to close later this month.

Businessman draws a statistical trend line
Details of Viatris' strategy will be provided at an Investor Day in Q1 • Source: Shutterstock

Mylan says it intends to provide details on Viatris’ strategy, including 2021 guidance, at an upcoming Investor Day to be held in late February or early March next year, following the anticipated closure of the firm’s proposed combination with Pfizer’s Upjohn off-patent and mature brands business on 16 November.

“At that time, the management team will outline how Viatris can deliver on its stated commitments and roadmap to maximize value creation, including the realization of $1bn in synergies and the generation of strong and accelerating free cash flows,” noted Mylan’s executive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.